{"filings":[{"id":94164,"accession_number":"0001437749-26-015039","cik":1625101,"company_name":"PULSE BIOSCIENCES, INC.","ticker":"PLSE","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Pulse Biosciences expands ATM to allow insider purchases; major holder and CEO indicate likely buying","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board authorized TD Cowen to sell shares to affiliates under existing ATM with up to $60M aggregate offering.","Robert Duggan (72% owner) and CEO Paul LaViolette indicate they are likely to purchase shares in near term.","No binding commitments or share counts; purchases would be at prevailing market bid or better."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1702558798.1310682,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94163,"accession_number":"0001437749-26-014547","cik":1625101,"company_name":"PULSE BIOSCIENCES, INC.","ticker":"PLSE","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Pulse Biosciences Q1 net loss $18.6M; accelerates NANOPULSE-AF enrollment to early Q4 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary Q1 2026: cash $68.3M, net loss $18.6M, cash used in ops $14.6M.","Product revenue $0.4M; R&D $12.6M, SG&A $6.6M; costs up $1.6M YoY.","NANOPULSE-AF U.S. IDE pivotal trial enrollment now expected to complete early Q4 2026.","NANOCLAMP-AF surgical trial enrollment target: end of H1 2027.","Added Dr. David Kenigsberg as full-time CMO and Liane Teplitsky as COO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1702558798.1310682,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94162,"accession_number":"0001437749-26-013383","cik":1625101,"company_name":"PULSE BIOSCIENCES, INC.","ticker":"PLSE","form_type":"8-K","filed_at":"2026-04-27T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Pulse Biosciences reports 100% 6-month and 96% 12-month ablation success in nPulse study","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sustained 100% procedural success at 6 months (95/95 evaluable patients by holter).","Sustained 96% procedural success at 12 months (51/53 evaluable patients).","90% Kaplan-Meier freedom from AF/AFL/AT at one year; low SAE rate of 1.7% (3/177).","Efficient procedure: left atrial dwell 18.6 min, total procedure 60.2 min, fluoroscopy 9.4 min.","Data presented at Heart Rhythm 2026 by Dr. Vivek Reddy; 177 patients treated across 7 European sites."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1702558798.1310682,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94161,"accession_number":"0001437749-26-012498","cik":1625101,"company_name":"PULSE BIOSCIENCES, INC.","ticker":"PLSE","form_type":"8-K","filed_at":"2026-04-16T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Pulse Biosciences posts investor deck with nsPFA cath lab study details and 2026 goals","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["New details disclosed on pivotal clinical study of nsPFA Cardiac Catheter for atrial fibrillation.","Next-generation nPulse cardiac catheter under development described in the deck.","2026 corporate goals summarized across electrophysiology, cardiac surgery, and soft tissue ablation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1702558798.1310682,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94160,"accession_number":"0001437749-26-011831","cik":1625101,"company_name":"PULSE BIOSCIENCES, INC.","ticker":"PLSE","form_type":"8-K","filed_at":"2026-04-09T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Pulse Biosciences appoints Liane Teplitsky COO; expands Dr. Kenigsberg as full-time CMO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Liane Teplitsky named COO effective April 8, 2026; oversees Clinical, Regulatory, Quality, Commercial functions.","Received inducement award: 700,000 stock options ($19.06) and 200,000 RSUs; vesting tied to market cap and revenue milestones.","Dr. David Kenigsberg expands to full-time Chief Medical Officer, continues active practice; will lead IDE pivotal study for nPulse catheter.","Two other new employees granted inducement options for 7,700 shares total at $19.06, time-vesting over four years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1702558798.1310682,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94159,"accession_number":"0001437749-26-011546","cik":1625101,"company_name":"PULSE BIOSCIENCES, INC.","ticker":"PLSE","form_type":"8-K","filed_at":"2026-04-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Pulse Biosciences enrolls first 7 patients in NANOPULSE-AF pivotal trial for nPulse AFib catheter","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First 7 patients treated at St. Bernards Medical Center by Devi Nair, MD.","Study plans to enroll ~215 participants across multiple sites; endpoints at 6 and 12 months.","Prior feasibility study showed 96% procedural success at 12 months and 100% acute success.","nPulse catheter uses nanosecond pulsed field ablation, integrated with Abbott EnSite X mapping.","Company aims to evaluate safety and efficacy for drug-resistant paroxysmal AF."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1702558798.1310682,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106347,"accession_number":"0001437749-26-010105","cik":1625101,"company_name":"PULSE BIOSCIENCES, INC.","ticker":"PLSE","form_type":"8-K","filed_at":"2026-03-27T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Pulse Biosciences awards CTO Darrin Uecker 100,000 RSUs for AFib product development","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Restricted stock units cover 100,000 shares of common stock, par value $0.001.","Grant vests in full on third anniversary of March 23, 2026 grant date.","Award made under Amended and Restated 2017 Equity Incentive Plan.","Compensation Committee granted for continued leadership in atrial fibrillation treatment product development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1702558798.1310682,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106346,"accession_number":"0001437749-26-008511","cik":1625101,"company_name":"PULSE BIOSCIENCES, INC.","ticker":"PLSE","form_type":"8-K","filed_at":"2026-03-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Pulse Biosciences realigns to accelerate AFib catheter program after strong clinical data","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["100% acute success at 6 months (75/75 patients); 96% durable PVI at 12 months (45/47).","Reducing headcount in sales/marketing; redirecting resources to cardiac catheter program and pivotal IDE study.","Streamlining soft-tissue ablation to focus on benign thyroid nodules and real-world data.","Late-breaking 12-month follow-up data to be presented at Heart Rhythm 2026 on April 25."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1702558798.1310682,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106345,"accession_number":"0001437749-26-007839","cik":1625101,"company_name":"PULSE BIOSCIENCES, INC.","ticker":"PLSE","form_type":"8-K","filed_at":"2026-03-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Pulse Biosciences enrolls first patients in thyroid cancer feasibility study of Vybrance nsPFA system","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First-in-human cases completed at Sarasota Memorial and MD Anderson for T1N0M0 papillary thyroid microcarcinoma.","Study is a multicenter, prospective feasibility trial; 30 patients planned across two sites.","System has FDA 510(k) clearance for soft tissue ablation; study runs under IDE for thyroid indications.","Primary endpoints: safety and effectiveness of nsPFA in treating tumors <1.5 cm."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1702558798.1310682,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106344,"accession_number":"0001437749-26-007283","cik":1625101,"company_name":"PULSE BIOSCIENCES, INC.","ticker":"PLSE","form_type":"8-K","filed_at":"2026-03-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Pulse Biosciences reports 74% avg volume reduction in benign thyroid nodule ablation at 15-22 months","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["21 patients monitored 15-22 months; average 74% volume reduction of benign thyroid nodules with no regrowth.","100% of patients highly satisfied with cosmetic appearance; 95% highly satisfied overall; no serious adverse events.","Data presented by Prof. Stefano Spiezia at North American Society for Interventional Thyroidology 2026 meeting.","CEO Paul LaViolette said non-cardiac nsPFA plans will be clarified in second half of 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1702558798.1310682,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106343,"accession_number":"0001437749-26-006629","cik":1625101,"company_name":"PULSE BIOSCIENCES, INC.","ticker":"PLSE","form_type":"8-K","filed_at":"2026-03-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Pulse Biosciences updates investor deck with nPulse catheter development, cites 'unprecedented' EU feasibility data","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Updated investor presentation posted on website includes summary financial info and product development update.","Next-generation nPulse cardiac catheter under development is highlighted.","Company strengthening focus on EP cardio ablation following 'unprecedented' EU feasibility study outcomes.","Presentation to be used in meetings with investors and analysts."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1702558798.1310682,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106336,"accession_number":"0001437749-26-006269","cik":1625101,"company_name":"PULSE BIOSCIENCES, INC.","ticker":"PLSE","form_type":"8-K/A","filed_at":"2026-03-02T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Pulse Biosciences CCO Kevin P. Danahy resigns effective immediately","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kevin P. Danahy, Chief Commercial Officer, resigned effective February 27, 2026.","No reason for the resignation was disclosed in the filing.","No replacement has been named at this time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1702558798.1310682,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106342,"accession_number":"0001437749-26-006141","cik":1625101,"company_name":"PULSE BIOSCIENCES, INC.","ticker":"PLSE","form_type":"8-K","filed_at":"2026-02-27T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Pulse Biosciences CCO Kevin Danahy resigns effective immediately","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kevin P. Danahy resigned as Chief Commercial Officer on February 27, 2026.","Resignation effective immediately, not due to any disagreement with the company.","Danahy was key to early commercialization efforts; company wishes him well.","No replacement named; CEO Paul LaViolette signed the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1702558798.1310682,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106341,"accession_number":"0001437749-26-004739","cik":1625101,"company_name":"PULSE BIOSCIENCES, INC.","ticker":"PLSE","form_type":"8-K","filed_at":"2026-02-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pulse Biosciences Q4 rev $264K, GAAP net loss $17.4M; FDA clears pivotal AF study","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 revenue $264K (vs $86K Q3), full-year revenue $350K. GAAP net loss Q4 $17.4M, full year $72.8M (vs $53.6M prior year).","Cash $80.7M at Dec 31, 2025 (down from $118.0M at Dec 31, 2024); Q4 cash used in ops $14.8M.","FDA approved pivotal IDE study for nPulse Cardiac Catheter System (paroxysmal AF); first patient expected in months, last patient Q4 2026.","Feasibility study: 100% procedural success at 6 months, 96% at 1 year for AF ablation.","Non-GAAP net loss Q4 $12.2M vs $10.4M prior year; full year $50.8M vs $36.9M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":350000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1702558798.1310682,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106340,"accession_number":"0001437749-26-004726","cik":1625101,"company_name":"PULSE BIOSCIENCES, INC.","ticker":"PLSE","form_type":"8-K","filed_at":"2026-02-19T23:59:59+00:00","items":["1.01","1.02","9.01"],"status":"ready","headline":"Pulse Biosciences enters $60M ATM equity distribution agreement with TD Cowen; terminates prior ATM","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered equity distribution agreement with TD Cowen to sell up to $59,976,196 of common stock via ATM offerings.","Terminated prior distribution agreement from July 2024 which had $59,976,196 unsold remaining.","TD Cowen will receive a 3% commission on gross sales; Company reimburses certain expenses.","Sales may occur at market prices; Company not obligated to sell any shares.","No specific use of proceeds disclosed; Company may sell shares from time to time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1702558798.1310682,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106339,"accession_number":"0001437749-26-003256","cik":1625101,"company_name":"PULSE BIOSCIENCES, INC.","ticker":"PLSE","form_type":"8-K","filed_at":"2026-02-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Pulse Biosciences reports 96% procedural success at 12 months for nPulse AF ablation study","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["100% procedural success at 6 months (75/75); 96% at 12 months (45/47) in first-in-human feasibility study.","Average procedure time 65 ± 28 min; left atrial dwell time 21 ± 13.3 min; fluoroscopy 9.8 ± 5.8 min.","Safety: 1.3% (2/150) subjects had a serious adverse event related to primary safety endpoint.","Data presented at AF Symposium 2026 by Dr. Vivek Reddy; 165 patients treated across 9 European sites.","Company plans to initiate pivotal IDE study in Europe and U.S. following these results."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1702558798.1310682,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106338,"accession_number":"0001437749-26-001225","cik":1625101,"company_name":"PULSE BIOSCIENCES, INC.","ticker":"PLSE","form_type":"8-K","filed_at":"2026-01-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Pulse Biosciences posts investor deck detailing progress on nPulse devices","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Updated investor presentation highlights recent progress on nPulse Vybrance Percutaneous Electrode, Cardiac Clamp, and Cardiac Catheter.","Presentation posted January 14, 2026; company expects to use it in investor meetings and analyst calls.","Deck available on company website under Investors section; no financial or clinical data disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1702558798.1310682,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106337,"accession_number":"0001437749-26-000938","cik":1625101,"company_name":"PULSE BIOSCIENCES, INC.","ticker":"PLSE","form_type":"8-K","filed_at":"2026-01-09T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Pulse Biosciences appoints Maria Sainz to Board of Directors and Audit Committee","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Maria Sainz elected to Pulse Biosciences Board and Audit Committee effective January 8, 2026.","Sainz brings over 30 years of healthtech experience; currently CEO of Hyperfine, Inc. (NASDAQ: HYPR).","Initial stock option grant of 50,000 shares; annual retainer of $55,000 plus $13,000 for Audit Committee.","Previously CEO of Concentric Medical, Aegea Medical, CardioKinetix; leadership at Guidant and Boston Scientific.","Serves on boards of Shockwave Medical (SWAV), Spectranetics (SPNC), Avanos (AVNS), Orthofix (OFIX)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1702558798.1310682,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122676,"accession_number":"0001437749-25-038213","cik":1625101,"company_name":"PULSE BIOSCIENCES, INC.","ticker":"PLSE","form_type":"8-K","filed_at":"2025-12-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Pulse Biosciences receives FDA IDE approval to initiate NANOPULSE-AF clinical study for paroxysmal atrial fibrillation","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved IDE for Pulse Biosciences' nPulse Cardiac Catheter System to treat paroxysmal atrial fibrillation in NANOPULSE-AF study.","Study is single-arm, multicenter, prospective; up to 30 sites (3 outside US) and up to 145 patients planned.","Ongoing European feasibility study has enrolled 150 patients; positive initial outcomes support device's potential.","nPulse uses nanosecond PFA aiming for complete circumferential lesion in single energy application without stacking.","CEO Paul LaViolette calls FDA approval a major milestone; follow-up data expected in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1702558798.1310682,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122675,"accession_number":"0001437749-25-037727","cik":1625101,"company_name":"PULSE BIOSCIENCES, INC.","ticker":"PLSE","form_type":"8-K","filed_at":"2025-12-12T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Pulse Biosciences annual meeting: all director nominees elected, say-on-pay approved, frequency set at 3 years","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Six director nominees (Duggan, LaViolette, Soni, Uecker, van den Broek, Zanganeh) elected with 51.8M-53.1M votes each.","Ratification of Deloitte & Touche as auditor for FY2025 approved with 63.1M votes for, 54K against.","Non-binding advisory vote on named executive officer compensation passed with 52.3M for, 0.9M against.","Advisory vote favored holding say-on-pay votes every three years (32.3M votes for 3 years vs. 20.8M for 1 year; 21.8K for 2 years).","All proposals passed; broker non-votes were 9.98M on director and say-on-pay items, none on auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":1702558798.1310682,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122674,"accession_number":"0001437749-25-037255","cik":1625101,"company_name":"PULSE BIOSCIENCES, INC.","ticker":"PLSE","form_type":"8-K","filed_at":"2025-12-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Pulse Biosciences initiates thyroid cancer study with MD Anderson; IDE approved","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDA-approved IDE for first-in-human feasibility study of nPulse Vybrance system in papillary thyroid microcarcinoma.","Study to commence early 2026, enroll 30 subjects at two sites, led by Dr. Victoria Banuchi at MD Anderson.","Preclinical studies ongoing for anaplastic thyroid carcinoma, a rare cancer with <5% five-year survival rate.","nPulse technology uses nonthermal nsPFA to limit scarring and damage to surrounding structures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1702558798.1310682,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122673,"accession_number":"0001437749-25-034658","cik":1625101,"company_name":"PULSE BIOSCIENCES, INC.","ticker":"PLSE","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Pulse Biosciences posts updated investor presentation on nPulse product progress","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Updated deck highlights recent progress on nPulse Vybrance Percutaneous Electrode, Cardiac Clamp, and Cardiac Catheter.","Presentation dated November 2025 is available on company website for investor meetings.","No specific quantitative milestones or financial data provided in the filing text."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1702558798.1310682,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122672,"accession_number":"0001437749-25-033348","cik":1625101,"company_name":"PULSE BIOSCIENCES, INC.","ticker":"PLSE","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pulse Biosciences Q3 2025 revenue $86k, GAAP net loss ($19.4M), cash $95.2M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $86k from limited market release of nPulse Vybrance system.","GAAP net loss ($19.4M) vs ($12.7M) in Q3 2024; Non-GAAP net loss ($13.5M) vs ($9.4M).","Cash $95.2M at Sep 30, 2025; operating cash burn $13.0M in Q3 2025.","Enrolled 40% of subjects in PRECISE-BTN thyroid nodule study; FDA IDE approved for NANOCLAMP AF surgical trial.","Treated 150 patients with nsPFA 360° catheter in European AF feasibility study; IDE submission filed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":86000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1702558798.1310682,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122671,"accession_number":"0001437749-25-031680","cik":1625101,"company_name":"PULSE BIOSCIENCES, INC.","ticker":"PLSE","form_type":"8-K","filed_at":"2025-10-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Pulse Biosciences enrolls first patient in NANOCLAMP AF study for AF treatment using nPulse system","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First procedure completed at St. Helena Hospital in St. Helena, CA with nPulse Cardiac Surgical System using nanosecond PFA.","NANOCLAMP AF is a single-arm, prospective multicenter study for safety/effectiveness of nPulse in concomitant AF procedures.","nPulse system granted FDA Breakthrough Device Designation in July 2024 and enrolled in FDA's TAP program.","Multiple U.S. and two international sites planned; study follows recent FDA IDE approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1702558798.1310682,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122670,"accession_number":"0001437749-25-030816","cik":1625101,"company_name":"PULSE BIOSCIENCES, INC.","ticker":"PLSE","form_type":"8-K","filed_at":"2025-10-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Pulse Biosciences reports 94% PVI success at 3 months in nPulse cardiac study","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All (100%) posterior box isolations acutely successful in high-dose cohort; 94% PVI success per vein at ~3 months.","Average total ablation time of 50 seconds with 13 applications; no esophageal or phrenic nerve damage reported.","No ablation-related severe or major adverse events in 44 treated patients across three European sites.","CEO confirms on track to initiate IDE study this year for nPulse Cardiac Surgical System."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1702558798.1310682,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122669,"accession_number":"0001437749-25-030184","cik":1625101,"company_name":"PULSE BIOSCIENCES, INC.","ticker":"PLSE","form_type":"8-K","filed_at":"2025-10-01T23:59:59+00:00","items":["5.07","8.01"],"status":"ready","headline":"Pulse Biosciences stockholders approve equity plan amendment and ratify director options","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved increasing Equity Plan shares by 2 million and changing Consultant definition.","Ratified options for up to 1.1 million shares, including 600,000 to directors (CEO LaViolette).","Director options have exercise price $15.65, 10-year term, vesting over annual meeting and monthly.","Proposal 1 voted 50,247,945 For vs 2,753,901 Against; Proposal 2 similarly approved.","Special Meeting held Sept 30, 2025; quorum of 53,011,701 shares represented."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1702558798.1310682,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139366,"accession_number":"0001437749-25-028560","cik":1625101,"company_name":"PULSE BIOSCIENCES, INC.","ticker":"PLSE","form_type":"8-K","filed_at":"2025-09-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Pulse Biosciences receives FDA IDE approval for nsPFA Cardiac Surgery Study NANOCLAMP AF","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA granted IDE approval for the NANOCLAMP AF study of nsPFA Cardiac Surgical System to treat atrial fibrillation.","Single-arm prospective study plans up to 20 sites (2 outside U.S.) enrolling up to 136 patients.","First-in-human EU feasibility study (since Aug 2024) treated over 40 patients with ablation times as short as 2.5 seconds.","nsPFA Cardiac Clamp received FDA Breakthrough Device Designation in July 2024 and is enrolled in the TAP program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1702558798.1310682,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139365,"accession_number":"0001437749-25-028093","cik":1625101,"company_name":"PULSE BIOSCIENCES, INC.","ticker":"PLSE","form_type":"8-K","filed_at":"2025-09-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Pulse Biosciences enrolls first patients in PRECISE-BTN study for benign thyroid nodules","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First successful procedures using nsPFA Percutaneous Electrode System for benign thyroid nodules (BTNs).","Multicenter IRB-approved study will enroll up to 50 patients across four sites.","Endpoints include safety, nodule volume reduction, symptom relief, quality of life, and cosmesis at 1, 3, 6, 12 months.","CEO notes ongoing commercial launch pilot phase alongside clinical study progression.","Principal investigator reports early positive results and organ-sparing potential."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1702558798.1310682,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139364,"accession_number":"0001437749-25-027725","cik":1625101,"company_name":"PULSE BIOSCIENCES, INC.","ticker":"PLSE","form_type":"8-K","filed_at":"2025-08-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Pulse Biosciences publishes FIH data for nsPFA thyroid nodule treatment in Thyroid journal","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Single-arm feasibility study by Prof. Spiezia at Ospedale del Mare, Naples, Italy; three cohorts.","Fully treated nodules (Cohort 3) showed up to 93% size reduction at 1 year (avg 86%), symptom relief as early as 2 weeks.","No intranodular fibrosis or scarring on follow-up ultrasounds.","nsPFA achieved 71% volume reduction in 1 month vs RFA's typical 6-month timeline for comparable shrinkage.","Publication in peer-reviewed journal Thyroid validates safety and effectiveness for benign nodules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1702558798.1310682,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139363,"accession_number":"0001437749-25-026195","cik":1625101,"company_name":"PULSE BIOSCIENCES, INC.","ticker":"PLSE","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pulse Biosciences Q2 net loss widens to $19.2M; advances nsPFA clinical programs with FDA IDE submissions","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net loss ($19.2M) vs ($11.4M) YoY; non-GAAP net loss ($13.7M) vs ($9.0M).","Cash $106.3M at June 30 (down from $119.3M at March 31); operating cash burn $12.8M in Q2.","FDA IDE applications submitted for nsPFA cardiac surgical clamp and 360° catheter AF pivotal studies.","Over 140 benign thyroid nodule patients treated; expanded pilot program; post-market study enrollment planned Q3 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1702558798.1310682,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139362,"accession_number":"0001437749-25-022675","cik":1625101,"company_name":"PULSE BIOSCIENCES, INC.","ticker":"PLSE","form_type":"8-K","filed_at":"2025-07-14T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Pulse Biosciences names Steven T. Weber as VP Accounting and principal accounting officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Steven T. Weber appointed VP of Accounting and Global Corporate Controller effective July 14, 2025, succeeding as principal accounting officer.","Weber brings 25+ years of experience; most recently SVP, Corporate Controller and PAO at IGM Biosciences.","Received start-date option for 55,000 shares at $16.03 (July 11 close), with time and performance-based vesting.","Performance vesting tied to market cap milestones: $1.5B, $2.25B, $3.0B, $4.0B sustained for 270 days or by set dates through 2029."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1702558798.1310682,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156945,"accession_number":"0001437749-25-015517","cik":1625101,"company_name":"PULSE BIOSCIENCES, INC.","ticker":"PLSE","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pulse Biosciences Q1 net loss widens to $16.8M; cash $119.3M; clinical milestones set","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net loss of $16.8M vs $10.1M in Q1 2024; non-GAAP net loss $11.4M vs $8.1M.","Cash and equivalents $119.3M as of March 31, 2025, down from $118.0M at Dec 31, 2024.","Costs and expenses $18.0M, up $7.4M YoY, driven by stock-based comp and organization expansion.","On track to launch nsPFA Percutaneous Electrode System in H2 2025; U.S. IDE for cardiac surgery and catheter systems expected mid-2025.","Treated 100 patients in Europe with nsPFA 360° catheter; data presented at HRS 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1702558798.1310682,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175327,"accession_number":"0001437749-25-009723","cik":1625101,"company_name":"PULSE BIOSCIENCES, INC.","ticker":"PLSE","form_type":"8-K","filed_at":"2025-03-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pulse Biosciences Q4 GAAP net loss widens to $19.4M; cash boosted to $118M on warrant exercises","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net loss of $19.4M in Q4 2024 vs $11.9M a year ago; full-year loss $53.6M vs $42.2M.","Cash and equivalents $118.0M as of Dec 31, 2024, up from $44.4M a year ago, driven by $47.9M in warrant proceeds.","Non-GAAP net loss Q4 $10.4M vs $8.3M; full-year $36.9M vs $33.8M; costs rose on stock comp and legal settlement.","Advanced soft tissue ablation pilot at 8 U.S. centers; expects U.S. thyroid clinical trial mid-2025.","Treated 30 patients in European AF feasibility study for surgical clamp; over 80 patients in catheter study."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1702558798.1310682,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175326,"accession_number":"0001437749-25-002664","cik":1625101,"company_name":"PULSE BIOSCIENCES, INC.","ticker":"PLSE","form_type":"8-K","filed_at":"2025-02-04T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Pulse Biosciences appoints Jon Skinner as CFO effective Feb 3, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jon Skinner appointed CFO effective Feb 3, 2025; previously VP at Copeland and Imperative Care.","Annual base salary $400,000, target bonus 50% of salary, sign-on bonus up to $56,000.","Granted option for 300,000 shares at $20.93 (closing on Jan 31, 2025) with four-year vesting.","Half of options vest time-based over 4 years; half vest based on market cap and revenue milestones.","Milestones include market caps of $2B to $5B and GAAP product revenues of $8M to $175M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1702558798.1310682,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175325,"accession_number":"0001437749-25-001727","cik":1625101,"company_name":"PULSE BIOSCIENCES, INC.","ticker":"PLSE","form_type":"8-K","filed_at":"2025-01-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Pulse Biosciences reports 92.4% PVI success at ~3 months in nsPFA catheter feasibility study","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["77 patients treated; first 30 evaluated at ~3 months remap with 92.4% PVI success (109/118 veins).","100% acute lesion success with conduction block; total PVI ablation time 11.6±4.5 minutes.","1 primary SAE (cardiac perforation) and 2 AEs (vertigo, creatinine elevation) all resolved.","Company on track to begin IDE study in 2025 for clinical validation.","Data presented at AF Symposium 2025; live case with 3D mapping on Abbott Ensite X System."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1702558798.1310682,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175324,"accession_number":"0001437749-25-001044","cik":1625101,"company_name":"PULSE BIOSCIENCES, INC.","ticker":"PLSE","form_type":"8-K","filed_at":"2025-01-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Pulse Biosciences posts updated investor deck highlighting CellFX nsPFA device progress","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Updated deck discloses progress on CellFX nsPFA 360 Cardiac Catheter development.","Progress also detailed for CellFX nsPFA Cardiac Clamp and Percutaneous Electrode.","Presentation dated January 2025; posted on company website under Investors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1702558798.1310682,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175323,"accession_number":"0001437749-25-001006","cik":1625101,"company_name":"PULSE BIOSCIENCES, INC.","ticker":"PLSE","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Pulse Biosciences appoints Paul LaViolette as CEO; grants 1.5M stock options with revenue/market cap milestones","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Paul LaViolette, former Co-Chairman, becomes CEO and President effective Jan 9, 2025.","Employment: $725k base salary, 70% target bonus, and option to purchase 1.5M shares at $18.43.","Options vest 30% time-based over 4 years; 70% performance-based tied to market cap ($3B–$9B) and GAAP revenue/margin targets.","Company also granted inducement options for 138,800 shares to 11 new employees at $18.55.","Pulse to present at JP Morgan Healthcare Conference Jan 15; nano-PFA cardiac systems in clinical studies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1702558798.1310682,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192271,"accession_number":"0001437749-24-038302","cik":1625101,"company_name":"PULSE BIOSCIENCES, INC.","ticker":"PLSE","form_type":"8-K","filed_at":"2024-12-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Pulse Biosciences redeems 150% warrants; $16.50 VWAP trigger met over 20 days","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["VWAP exceeded $16.50 for 20 consecutive trading days; average VWAP of $18.85 during period.","Redemption date Feb 5, 2025; exercise price $11.00; unexercised warrants redeemed for $0.01.","If all warrants exercised, company receives additional $66M gross proceeds (total $60M from rights offering).","Second tranche (200% warrants) not being redeemed at this time.","Warrants issued in July 2024 rights offering; notice to be delivered Dec 27, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1702558798.1310682,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192270,"accession_number":"0001437749-24-036862","cik":1625101,"company_name":"PULSE BIOSCIENCES, INC.","ticker":"PLSE","form_type":"8-K","filed_at":"2024-12-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Pulse Biosciences CEO Barrett resigns; Danahy, Uecker named interim executives","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Burke T. Barrett resigns effective Dec 6, 2024; also leaves board Dec 2, 2024.","Resignation not due to any disagreement; company affirms development and clinical plans on track.","Severance: 12 months base salary (24 installments), $106,009.61 bonus, partial vesting of 101,000 options at $7.45, COBRA.","Chief Commercial Officer Kevin Danahy and CTO Darrin Uecker serve as interim principal executive and financial officers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1702558798.1310682,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192269,"accession_number":"0001437749-24-036234","cik":1625101,"company_name":"PULSE BIOSCIENCES, INC.","ticker":"PLSE","form_type":"8-K","filed_at":"2024-11-26T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Controlling stockholder Robert Duggan cleared to buy up to 500k PLSE shares by Dec 10","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Robert W. Duggan, controlling stockholder and Co-Chairman, authorized to purchase up to 500,000 shares of common stock through December 10, 2024.","Purchases are at Mr. Duggan's sole discretion and depend on market conditions.","Insider Trading Policy clearance obtained for the potential transactions.","No obligation to purchase any shares; disclosure provided under Regulation FD."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1702558798.1310682,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192268,"accession_number":"0001437749-24-032770","cik":1625101,"company_name":"PULSE BIOSCIENCES, INC.","ticker":"PLSE","form_type":"8-K","filed_at":"2024-10-31T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Pulse Biosciences: nano-PFA reduces benign thyroid nodule volume >50% in feasibility study","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First-in-human study (30 patients) shows ≥50% nodule volume reduction and symptomatic relief within 1 month.","Results presented at 2024 American Thyroid Association Annual Meeting by PI Dr. Stefano Spiezia.","No residual fibrosis or scarring observed; potential advantage over thermal ablation and surgery.","Company plans to commence pivotal trial mid-2025 to support U.S. labeling indication.","Study NCT06117085 fully enrolled; long-term follow-up ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1702558798.1310682,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192267,"accession_number":"0001437749-24-032613","cik":1625101,"company_name":"PULSE BIOSCIENCES, INC.","ticker":"PLSE","form_type":"8-K","filed_at":"2024-10-30T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Pulse Biosciences Q3 net loss $12.7M; appoints Dr. Kenigsberg as CMO for Electrophysiology","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net loss $12.7M in Q3 2024 vs $10.6M in Q3 2023; cash $79M including $60M rights offering.","Placed nsPFA Percutaneous Electrode System at 7 US pilot sites; pivotal trial for thyroid nodules expected mid-2025.","Over 50 patients treated with nano-PFA 360 catheter in European feasibility study; two additional study sites engaged.","Appointed Dr. David Kenigsberg as CMO of Electrophysiology; added Dr. Andrea Natale as medical advisor.","Cash burn $8.5M in Q3; warrants could raise up to $66M at $11/share, exercisable immediately."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1702558798.1310682,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208759,"accession_number":"0001437749-24-026104","cik":1625101,"company_name":"PULSE BIOSCIENCES, INC.","ticker":"PLSE","form_type":"8-K","filed_at":"2024-08-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Pulse Biosciences posts updated investor presentation on website; no new financial data disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Updated deck highlights progress on CellFX nsPFA 360 Cardiac Catheter, Cardiac Surgery System, and Percutaneous Electrode.","Investor presentation is dated August 2024 and available on company's website.","No specific milestones, clinical data, or financial guidance included in filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1702558798.1310682,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208758,"accession_number":"0001437749-24-026060","cik":1625101,"company_name":"PULSE BIOSCIENCES, INC.","ticker":"PLSE","form_type":"8-K","filed_at":"2024-08-12T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Pulse Biosciences reports Q2 prelim costs $11.7M; appoints Paul LaViolette as Co-Chairman","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["GAAP costs and expenses $11.7M for Q2 2024; non-GAAP $9.4M; cash $26.2M as of June 30, excluding $60M rights offering closed July 2024.","Oversubscribed rights offering generated $60M gross proceeds; warrants could add up to $66M.","Completed first US soft tissue ablation procedure after FDA clearance; pivotal trial for benign thyroid nodules planned in 2025.","Received FDA Breakthrough Device Designation for Cardiac Surgery System for AF; first European epicardial ablations completed.","Appointed Paul LaViolette as Co-Chairman of Board; he brings 40 years medtech experience from Boston Scientific."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1702558798.1310682,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208757,"accession_number":"0001437749-24-025296","cik":1625101,"company_name":"PULSE BIOSCIENCES, INC.","ticker":"PLSE","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Pulse Biosciences treats first two patients in first-in-human study of nano-PFA Cardiac Surgery System for AFib","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Successfully treated first two AFib patients using nano-PFA Cardiac Surgery System at St. Antonius Hospital, Netherlands.","Feasibility study is multicenter, up to 30 patients, with chronic isolation confirmed at ~3 months via catheter remapping.","Cardiac Surgery System enrolled in FDA's TAP program and holds Breakthrough Device Designation (granted July 2024).","Plans to submit IDE for U.S. clinical work and begin pivotal study in early 2025, pursuing PMA for commercialization."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1702558798.1310682,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208756,"accession_number":"0001193125-24-178827","cik":1625101,"company_name":"PULSE BIOSCIENCES, INC.","ticker":"PLSE","form_type":"8-K","filed_at":"2024-07-15T23:59:59+00:00","items":["1.01","2.02","9.01"],"status":"ready","headline":"Pulse Biosciences enters $60M ATM equity facility; prelim Q2 net loss $10.7-12.7M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to $60M at-the-market offering via Canaccord Genuity and Needham; commission up to 3%.","Preliminary Q2 2024 cash and cash equivalents $26.0-26.5M (excl. $60M rights offering close in July).","GAAP net loss $10.7-12.7M; non-GAAP net loss $8.7-9.7M.","GAAP costs and expenses $11-13M; non-GAAP costs $9-10M; adjustments include stock-based comp and D&A."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1702558798.1310682,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208755,"accession_number":"0001437749-24-022297","cik":1625101,"company_name":"PULSE BIOSCIENCES, INC.","ticker":"PLSE","form_type":"8-K","filed_at":"2024-07-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Pulse Biosciences receives FDA Breakthrough Device Designation for nsPFA Cardiac Surgery System for AF treatment","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA Breakthrough Device Designation for CellFX nsPFA Cardiac Surgery System to treat atrial fibrillation.","Designation provides expedited development and prioritized review; company plans PMA approval pathway.","Preclinical data shows single <2-second application creates transmural ablation, ~20x faster than thermal RF.","First-in-human cases expected in Netherlands soon; pivotal clinical trial planned for 2025.","No risk of thermal spread due to non-thermal nano-PFA mechanism, potentially safer than current options."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1702558798.1310682,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208760,"accession_number":"0001437749-24-022162","cik":1625101,"company_name":"PULSE BIOSCIENCES, INC.","ticker":"PLSE","form_type":"8-K","filed_at":"2024-07-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Pulse Biosciences closes $60M rights offering at $10/unit, oversubscribed 138%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Raised $60M gross from 6M units; each unit = 1 share + 2 warrants to buy 0.5 share at $11.","Subscriptions exceeded $83M from 800+ accounts, including Executive Chairman Robert Duggan.","Post-offering shares outstanding: 61,228,332; warrants for up to ~6M additional shares issued.","Proceeds to fund CellFX nsPFA products: Percutaneous Electrode, Cardiac Clamp, 360° Catheter.","Warrants exercisable immediately for 5 years; redeemable if stock exceeds $16.50 or $22 for 20 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1702558798.1310682,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226499,"accession_number":"0001437749-24-021615","cik":1625101,"company_name":"PULSE BIOSCIENCES, INC.","ticker":"PLSE","form_type":"8-K","filed_at":"2024-06-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Pulse Biosciences rights offering oversubscribed, raises $60M; Duggan to hold ~72%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering oversubscribed at 138%, receiving over $83M in subscriptions vs $60M limit.","Expected gross proceeds of $60M from sale of ~6M units at $10/unit.","Executive Chairman Robert Duggan subscribed for ~5M units, boosting his ownership to ~72%.","Warrants could generate up to $66M additional proceeds if exercised; exercise price $11/share.","Units consist of one share and two warrants; warrants expire in five years with redemption conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1702558798.1310682,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226498,"accession_number":"0001437749-24-019669","cik":1625101,"company_name":"PULSE BIOSCIENCES, INC.","ticker":"PLSE","form_type":"8-K","filed_at":"2024-06-07T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Pulse Biosciences 2024 annual meeting elects five directors; Spray not reelected","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Director Shelley Spray did not stand for reelection at June 6, 2024 meeting; no disagreement with company.","Elected directors: Duggan, Soni, Uecker, van den Broek, Zanganeh – each with 39.5-40.7M votes for.","Ratification of Deloitte & Touche as auditor for FY 2024 passed: 50.0M for, 5,763 against.","Total shares outstanding not disclosed; broker non-votes of 9.27M were present on director elections."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1702558798.1310682,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2024-06-07T23:59:59+00:00|226498"}